- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03020862
Beetroot Juice - Effects on Performance in Chronic Obstructive Pulmonary Disease Patients (COPD)
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Aarhus, Denmark, 8000
- Sport Science, Department of Public Health, Aarhus University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Moderate-severe Chronics Obstructive Pulmonary Disease (COPD) (FEV1 <80% of predicted).
Exclusion Criteria:
- Smoking,
- failure to complete physical testing,
- on-going participation in rehabilitation programs,
- pacemaker or use of nicotine products,
- oxygen mask,
- beta blockers,
- antibacterial mouthwash,
- chewing gum or stomach-neutralizing medicine during the intervention.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Placebo ---> Dietary beetroot
Placebo was administrated in the first period of the cross-over trial, while the intervention beverage Dietary Beetroot juice was administrated in the second period of the trial. The placebo: was an NO3- negligble drink from James White Drinks England (Beet-it), which was otherwise similar to the dietary beetroot juice in nutrient composition, smell and appearance. Dose: 2x70 mL consumed twice a day for six days. Intervention beverage, Dietary beetroot juice:Consumed as beetroot juice from James White Drinks England (Beet-it) and contained 300 mg dietary nitrate. Dose: 2x70 mL consumed twice a day for six days. |
Consumed as concentrated beetroot juice from James White Drinks England (Beet-it) and contained 300 mg dietary nitrate.
Dose: 2x70 mL consumed twice a day for six days.
|
Experimental: Dietary beetroot juice --> Placebo
The intervention beverage Dietary beetroot juice was administrated in the first period of the cross-over trial, while placebo was administrated in the second period of the trail Intervention beverage, Dietary beetroot juice:Consumed as beetroot juice from James White Drinks England (Beet-it) and contained 300 mg dietary nitrate.
Dose: 2x70 mL consumed twice a day for six days.
The placebo: was an NO3- negligble drink from James White Drinks England (Beet-it), which was otherwise similar to the dietary beetroot juice in nutrient composition, smell and appearance.
Dose: 2x70 mL consumed twice a day for six days.
|
Consumed as concentrated beetroot juice from James White Drinks England (Beet-it) and contained 300 mg dietary nitrate.
Dose: 2x70 mL consumed twice a day for six days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Physical performance on 6-min walk test (6MWT)
Time Frame: 6 minutes
|
6 minutes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Blood Pressure
Time Frame: At baseline and 150 minutes after consumption of beverages
|
At baseline and 150 minutes after consumption of beverages
|
|
Plasma Nitrite concentration
Time Frame: Baseline, 150 and 210 minutes after consumption of beverages
|
Baseline, 150 and 210 minutes after consumption of beverages
|
|
Oxygen consumption during submaximal cycling
Time Frame: Two trials of 6 minutes duration (10 min break between trials)
|
Two trials of 6 minutes duration (10 min break between trials)
|
|
Physical activity level
Time Frame: Six days
|
Measured all intervention days except on the day of testing
|
Six days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mette Hansen, Aarhus University, Department for Public Health, Section for Sport Sciene
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- D2013A2014
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Obstructive Pulmonary Disease Moderate
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
Canandaigua VA Medical CenterRecruitingChronic Obstructive Pulmonary Disease ModerateUnited States
-
Verona Pharma plcCompletedChronic Obstructive Pulmonary Disease Moderate
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
AstraZenecaMedImmune LLCCompletedModerate to Very Severe Chronic Obstructive Pulmonary DiseaseUnited States, Denmark, France, Sweden, Thailand, Vietnam, Belgium, Brazil, Peru, Philippines, Turkey, Taiwan, Argentina, Australia, Israel, Poland, Ukraine, Slovenia, Serbia, Mexico, Bulgaria, Colombia, New Zealand, Chile, Norway, Croatia
-
AstraZenecaMedImmune LLCCompletedModerate to Very Severe Chronic Obstructive Pulmonary DiseaseUnited States, Canada, Germany, Italy, Netherlands, Spain, United Kingdom, Poland, Japan, Austria, Korea, Republic of, Russian Federation, South Africa, Czechia, Hungary, Romania, Switzerland
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Chiesi Farmaceutici S.p.A.CompletedModerate to Severe Chronic Obstructive Pulmonary Disease (COPD)Bulgaria, Germany, Hungary, Poland, Russian Federation, United Kingdom
-
Glenmark Specialty S.A.CompletedMild to Moderate Chronic Obstructive Pulmonary Disease (COPD)United States
-
Meridigen Biotech Co., Ltd.Active, not recruitingChronic Obstructive Pulmonary Disease ModerateTaiwan
Clinical Trials on Dietary beetroot juice
-
Royal College of Surgeons, IrelandUniversity College Dublin; Connolly Hospital BlanchardstownCompletedHypertension
-
Royal College of Surgeons, IrelandUniversity College Dublin; Connolly Hospital BlanchardstownCompletedChronic Obstructive Pulmonary DiseaseIreland
-
Royal College of Surgeons, IrelandUniversity College Dublin; Connolly Hospital BlanchardstownCompletedCardiomyopathy
-
Royal College of Surgeons, IrelandUniversity College Dublin; Connolly Hospital BlanchardstownCompletedObstructive Sleep Apnoea SyndromeIreland
-
Universidad Francisco de VitoriaUniversity of Alcala; University of SevilleCompleted
-
Bangor UniversityCompleted
-
University Hospital, GhentUniversity GhentTerminated
-
University of ManchesterCompleted
-
Queen Mary University of LondonCompleted
-
University of Colorado, BoulderRecruitingChronic Kidney DiseaseUnited States